Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections
Biosimilars represent medicinal products that exhibit a high degree of similarity to an already sanctioned reference biologic agent, with negligible clinically significant disparities concerning safety, purity, or potency. These therapeutic modalities are formulated as economically viable substitute...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/5/581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849711735518265344 |
|---|---|
| author | Mohamed Halawa Ramez M. Rashad ElSayed Tope Aderibigbe Precious M. Newman Briana E. Reid Valerie J. Carabetta |
| author_facet | Mohamed Halawa Ramez M. Rashad ElSayed Tope Aderibigbe Precious M. Newman Briana E. Reid Valerie J. Carabetta |
| author_sort | Mohamed Halawa |
| collection | DOAJ |
| description | Biosimilars represent medicinal products that exhibit a high degree of similarity to an already sanctioned reference biologic agent, with negligible clinically significant disparities concerning safety, purity, or potency. These therapeutic modalities are formulated as economically viable substitutes for established biologics, thereby facilitating increased accessibility to sophisticated treatments for a range of medical conditions, including infectious diseases caused by bacterial, fungal, and viral pathogens. The current landscape of biosimilars includes therapeutic proteins, such as monoclonal antibodies, antimicrobial peptides, antiviral peptides, and antifungal peptides. Here, we discuss the obstacles inherent in the development of biosimilars, including the rapid mutation rates of pathogens. Furthermore, we discuss innovative technologies within the domain, including antibody engineering, synthetic biology, and cell-free protein synthesis, which exhibit potential for improving the potency and production efficiency of biosimilars. We end with a prospective outlook to highlight the importance and capacity of biosimilars to tackle emerging infectious diseases, highlighting the imperative need for ongoing research and financial commitment. |
| format | Article |
| id | doaj-art-ea3b03ddbf694d6dba73960f88eb5cee |
| institution | DOAJ |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-ea3b03ddbf694d6dba73960f88eb5cee2025-08-20T03:14:32ZengMDPI AGPharmaceutics1999-49232025-04-0117558110.3390/pharmaceutics17050581Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral InfectionsMohamed Halawa0Ramez M. Rashad ElSayed1Tope Aderibigbe2Precious M. Newman3Briana E. Reid4Valerie J. Carabetta5Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USACancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria P.O. Box 21521, EgyptDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USADepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USADepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USADepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USABiosimilars represent medicinal products that exhibit a high degree of similarity to an already sanctioned reference biologic agent, with negligible clinically significant disparities concerning safety, purity, or potency. These therapeutic modalities are formulated as economically viable substitutes for established biologics, thereby facilitating increased accessibility to sophisticated treatments for a range of medical conditions, including infectious diseases caused by bacterial, fungal, and viral pathogens. The current landscape of biosimilars includes therapeutic proteins, such as monoclonal antibodies, antimicrobial peptides, antiviral peptides, and antifungal peptides. Here, we discuss the obstacles inherent in the development of biosimilars, including the rapid mutation rates of pathogens. Furthermore, we discuss innovative technologies within the domain, including antibody engineering, synthetic biology, and cell-free protein synthesis, which exhibit potential for improving the potency and production efficiency of biosimilars. We end with a prospective outlook to highlight the importance and capacity of biosimilars to tackle emerging infectious diseases, highlighting the imperative need for ongoing research and financial commitment.https://www.mdpi.com/1999-4923/17/5/581antibacterial biosimilarsantifungal biosimilarsantimicrobial peptidesantiviral biosimilarsinfection managementmonoclonal antibodies |
| spellingShingle | Mohamed Halawa Ramez M. Rashad ElSayed Tope Aderibigbe Precious M. Newman Briana E. Reid Valerie J. Carabetta Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections Pharmaceutics antibacterial biosimilars antifungal biosimilars antimicrobial peptides antiviral biosimilars infection management monoclonal antibodies |
| title | Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections |
| title_full | Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections |
| title_fullStr | Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections |
| title_full_unstemmed | Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections |
| title_short | Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections |
| title_sort | biosimilars targeting pathogens a comprehensive review of their role in bacterial fungal parasitic and viral infections |
| topic | antibacterial biosimilars antifungal biosimilars antimicrobial peptides antiviral biosimilars infection management monoclonal antibodies |
| url | https://www.mdpi.com/1999-4923/17/5/581 |
| work_keys_str_mv | AT mohamedhalawa biosimilarstargetingpathogensacomprehensivereviewoftheirroleinbacterialfungalparasiticandviralinfections AT ramezmrashadelsayed biosimilarstargetingpathogensacomprehensivereviewoftheirroleinbacterialfungalparasiticandviralinfections AT topeaderibigbe biosimilarstargetingpathogensacomprehensivereviewoftheirroleinbacterialfungalparasiticandviralinfections AT preciousmnewman biosimilarstargetingpathogensacomprehensivereviewoftheirroleinbacterialfungalparasiticandviralinfections AT brianaereid biosimilarstargetingpathogensacomprehensivereviewoftheirroleinbacterialfungalparasiticandviralinfections AT valeriejcarabetta biosimilarstargetingpathogensacomprehensivereviewoftheirroleinbacterialfungalparasiticandviralinfections |